Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: Preclinical and clinical efficacy

Pharmacological Reports

Volumn 65, Issue 6, 2013, Pages 1535-1544

  Rogóz, Zofia ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Antidepressants; Atypical antipsychotics; Augmentation; Depression; Preclinical and clinical studies

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLOZAPINE; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; MILNACIPRAN; MIRTAZAPINE; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; REBOXETINE; RISPERIDONE; SERTRALINE; VENLAFAXINE; VOLINANSERIN; YOHIMBINE;

ADD ON THERAPY; ADJUVANT THERAPY; ADVERSE OUTCOME; AKATHISIA; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HUMAN; INCREASED APPETITE; LOW DRUG DOSE; METABOLIC DISORDER; MICRODIALYSIS; NEUROCHEMISTRY; NONHUMAN; PREFRONTAL CORTEX; REVIEW; SEDATION; SOMNOLENCE; TREATMENT RESISTANT DEPRESSION; WEIGHT GAIN;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSION; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS;

EID: 84894205935     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/s1734-1140(13)71515-9     Document Type: Article

References (50)

1. Alexopoulos GS, Cansuso CM, Gharabawi GM, Bossie CA, Greenspan A, Turkoz I, Reynolds III C: Placebocontrolled study of relapse prevention with risperidone augmentation in older patients with resistant depression. Am J Geriatr Psychiatry, 2008, 16, 21-30.
2. Amsterdam JD, Hornig-Rohan M: Treatment algorithms in treatment-resistant depression. Psychiatry Clin North Am, 1996, 19, 371-386. (Pubitemid 26184108)
3. Bauer M, El-Khalili N, Datto C, Szamosi J, Eriksson H: A pooled analysis of two randomized, placebo-controlled studies, of extended release quetiapine fumarate to antidepressant therapy in patients with major depressive disorder. J Affect Disord, 2010, 127, 19-30.
4. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M: Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebocontrolled, double-blind study. J Clin Psychiatry, 2009, 70, 540-549.
5. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH et al.: Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS, 2009, 14, 197-206.
6. Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, doubleblind, placebo-controlled study. J Clin Psychiatry, 2007, 68, 843-853. (Pubitemid 47015482)
7. Bourin M, Chenu F, Prica C, Hascoët M: Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology, 2009, 206, 97-107.
8. Burda K, Czubak A, Kuoe K, Nowakowska E, Ratajczak P, Zin J: Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats. Pharmacol Rep, 2011, 63, 898-907.
9. Carroll BJ: Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology, 2008, 33, 2546-2547.
10. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G: A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety, 2006, 23, 364-372. (Pubitemid 44619788)
11. Denys D, Klompmakers AA, Westenberg HGM: Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacology, 2004, 176, 195-203. (Pubitemid 39517949)
12. Dhir A, Kulkarni SK: Risperidone, an atypical antipsychotic enhances the antidepressant-like effect of venlafaxine or fluoxetine: Possible involvement of alpha-2 adrenergic receptors. Neurosci Lett, 2008, 445, 83-88.
13. El-Khalili N, Joyce M, Atkinson S, Buynaki RJ, Datto C, Lindgren P, Eriksson H: Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebocontrolled study. Int J Neuropsychopharmacol, 2010, 13, 917-932.
14. Huang M, Ichiwara J, Li Z, Dai J, Meltzer HY: Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex. Psychopharmacology, 2006, 185, 274-281.
15. Ichikawa J, Kuroki T, Dai J, Meltzer HY: Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur J Pharmacol, 1998, 351, 163-171. (Pubitemid 28312927)
16. Jordan S, Koprivica V, ChenR, Tottori K, Kikuchi T, Altar A: The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol, 2002, 441, 137-140. (Pubitemid 34626163)
17. Kamei J, Miyata S, Sunohara T, Kamei A, Shimada M, Ohsawa M: Potentiation of the antidepressant-like effect of fluoxetine by aripiprazole in mice tail suspension test. J Pharmacol Sci, 2008, 108, 381-384.
18. Kamiñska K, Goembiowska K, Rogó Z: The effect of risperidone on the fluoxetine-induced changes in extracellular dopamine, serotonin and noradrenaline in the rat frontal cortex. Pharmacol Rep, 2013, 65, 1144-1151.
19. Kato M, Chang C-M: Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression. CNS Drugs, 2013, 27, Suppl 1, S11-S19.
20. Keitner GI, Garlow SJ, Ryan CE, Ninan PT, Solomon DA, Nemeroff CB, Keller MB: A randomized, placebocontrolled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. J Psychiatry Res, 2009, 43, 205-214.
21. Kikuchi T, Tottori K, UwahodoY, Hirose T, Miwa T, Oshiro Y, Morita S: 7-(4-[4-(2,3-Dichlorophenyl)-piperazinyl]butyloxy)-3,4-dihydro-2(1H) -quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther, 1995, 274, 329-336.
22. Maes M, Meltzer HY: The serotonin hypothesis of major depression. In: Psychopharmacology: The Fourth Generation of Progress. Eds. Bloom FE, Kupfer DJ, Raven Press Ltd., New York, 1995, 933-944.
23. Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, Canuso CM, Kujawa MJ, Gharabawi-Garibaldi GM: Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann Intern Med, 2007, 147, 592-602.
24. Marcus MM, Jardemark K, Malmerfelt A, Gertow J, Konradsson-Geuken Ä, Svensson TH: Augmentation of escitalopram, but not citalopram or R-citalopram, of the effects of low-dose risperidone: behavioral, biochemical, and electeophysiological evidence. Synapse, 2012, 66, 277-290.
25. Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH et al.: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol, 2008, 28, 156-165. (Pubitemid 351417120)
26. McIntyre A, Gendron A: Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety, 2007, 24, 487-494. (Pubitemid 350086262)
27. Meltzer HY: The mechanism of action of novel antipsychotic drugs. Schizophr Bull, 1991, 17, 263-287.
28. Millan MJ, Dekeyne A, Gobert A: Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology, 1998, 37, 953-955.
29. Nakayama K, Sakurai T, Katsu H: Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Brain Res Bull, 2004, 63, 237-231.
30. Pessia M, Jiang ZG, North RA, Johnson SW: Actions of 5-hydroxytryptamine on ventral tegmental area neurons of the rat in vitro. Brain Res, 1994, 654, 324-330.
31. Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, Turkoz I et al.: Effects of risperidone augmentation in patients with treatmentresistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology, 2006, 31, 2505-2513. (Pubitemid 44607069)
32. Reeves H, Batra S, May RS, Zhang R, Dahl DC, Li X: Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. J Clin Psychiatry, 2008, 69, 1228-1336.
33. Richelson E, Souder T: Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci, 2000, 68, 29-39.
34. Rogó Z: Effects of co-treatment with mirtazapine and low doses of risperidone on the immobility time in the forced swimming test in mice. Pharmacol Rep, 2010, 62, 1191-1196.
35. Rogó Z, Kabziñski M: Enhancement of the antiimmobility action of antidepressants by risperidone in the forced swimming test in mice. Pharmacol Rep, 2011, 63, 1533-1538.
36. Rogó Z, Kabziñski M, Sadaj W, Rachwalska P, Gdek-Michalska A: Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test. Pharmacol Rep, 2012, 64, 1391-1399.
37. Schatzberg AF, Schildkraut J: Recent studies on norepinephrine systems in mood disorders. In: Psychopharmacology: The Fourth Generation of Progress. Eds. Bloom FE, Kupfer DJ, Raven Press Ltd., New York, 1995, 911-920.
38. Schilstrõm B, Konradsson-Geuken A, Ivanov V, Gertow J, Feltmann K, Marcus MM, Jardemark K, Svensson TH: Effect of S-citalopram, citalopram, and R-citalopram on the firing patterns of dopamine neurons in the ventral tegmental area, N-methyl-D-aspartate receptor-mediated transmission in the medial prefrontal cortex and cognitive function in the rat. Synapse, 2011, 65, 357-367.
39. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE: Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl), 1996, 124, 57-73. (Pubitemid 26112775)
40. Shelton RC: Treatment options for refractory depression. J Clin Psychiatry, 1999, 60, Suppl 4, 57-61.
41. Shelton RC, Papakostas GI: Augmentation of antidepressants with atypical antypsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand, 2008, 117, 253-259. (Pubitemid 351350599)
42. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR et al.: A novel augmentation strategy for treating resistant major depression. Am J Psychiatry, 2001, 158, 131-134. (Pubitemid 32047260)
43. Shelton RC, Williamson DJ, Corya SA, Sanger TM, Van Campen LE, Case M, Briggs SD, Tollefson GD: Olanzapine/fluoxetine combination for treatmentresistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry, 2005, 66, 1289-1297. (Pubitemid 41546509)
44. Steffens DC, Nelson JC, Eudicone JM, Andersson C, Yang H, Tran QV, Forbes RA et al.: Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. Int J Geriatr Psychiatry, 2011, 26, 564-572.
45. Thase ME, Corya SA, Osuntokun O, Case M, Henley DB, Sanger TM, Watson SB, Dubé S: A randomized, double-blind comparison olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry, 2007, 68, 224-236. (Pubitemid 46362643)
46. Trivedi MH, Thase ME, Osuntokun O, Henley DB, Case M, Watson SB, Campbell GM, Corya SA: An intergrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. J Clin Psychiatry, 2009, 70, 387-396.
47. Willner P: Dopaminergic mechanism in depression and mania. In: Psychopharmacology: The Fourth Generation of Progress. Eds. Bloom FE, Kupfer DJ, Raven Press Ltd., New York, 1995, 921-931.
48. Wright BM, Eiland III EH, Lorenz R: Augmentation with atypical antipsychotics for depression: A review of evidence-based support from the medical literature. Pharmacotherapy, 2013, 33, 344-359.
49. Zajdel P, Marciniec K, Maoelankiewicz A, Grychowska K, Sataa G, Duszyñska B, Lenda T et al.: Antidepressant and antipsychotic activity of new quinaline-and isoquinaline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT1A/5-HT2A/5-HT7 and dopamine D2/D3 receptors. Eur J Med Chem, 2013, 60, 42-50.
50. Zhang W, Perry KW, Wong DT, Potts BD, Bao JQ, Tollefson GD, Bymaster FP: Synergistic effect of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology, 2000, 23, 250-262. (Pubitemid 30609659)